Bystander Elimination of Antigen Loss Variants in Established Tumors
Overview
Molecular Biology
Affiliations
Cancers express antigens that are targets for specific cytotoxic T lymphocytes (CTLs). However, cancer cells are genetically unstable. Consequently, sub-populations of cancer cells that no longer express the target antigen may escape destruction by CTLs and grow progressively. We show that cytotoxic T cells indirectly eliminate these antigen loss variants (ALVs) in a model system when the parental cancer cells express sufficient antigen to be effectively cross-presented by the tumor stroma. When the parental tumor expressed lower levels of antigen, cytotoxic T cells eradicated the antigen-positive parental cancer cells, but the ALVs escaped, grew and killed the host. By contrast, when the parental tumor expressed higher levels of antigen, cytotoxic T cells eradicated not only the parental cancer cells but also the ALVs. This 'bystander' elimination of ALVs required stromal cells expressing major histocompatibility complex (MHC) molecules capable of presenting the antigen, and occurred in tumors showing evidence of stromal destruction. ALVs were apparently eliminated indirectly when tumor-specific CTLs killed stromal cells that were cross-presenting antigen produced by and released from antigen-positive cancer cells. These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells.
Wolf S, Leisegang M, Steiner M, Wallace V, Kiyotani K, Hu Y Sci Immunol. 2024; 9(99):eadp6529.
PMID: 39270007 PMC: 11560124. DOI: 10.1126/sciimmunol.adp6529.
Sun B, Zhang D, Gan W, Wu J, Wang Z, Sun G J Cancer Res Clin Oncol. 2024; 150(7):348.
PMID: 39002018 PMC: 11246275. DOI: 10.1007/s00432-024-05869-1.
Lischer C, Eberhardt M, Flamann C, Berges J, Guse E, Wessely A J Immunother Cancer. 2024; 12(5).
PMID: 38724462 PMC: 11086525. DOI: 10.1136/jitc-2023-008104.
Distinct spatiotemporal dynamics of CD8 T cell-derived cytokines in the tumor microenvironment.
Hoekstra M, Slagter M, Urbanus J, Toebes M, Slingerland N, de Rink I Cancer Cell. 2024; 42(1):157-167.e9.
PMID: 38194914 PMC: 10783802. DOI: 10.1016/j.ccell.2023.12.010.
Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N, Poncette L, Blankenstein T J Immunother Cancer. 2023; 11(2).
PMID: 36822673 PMC: 9950979. DOI: 10.1136/jitc-2022-006001.